山外山(688410) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 reached ¥193,032,111.71, representing a year-on-year increase of 187.14%[5] - Net profit attributable to shareholders was ¥74,586,123.06, a significant increase of 866.83% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥71,078,708.92, reflecting a year-on-year growth of 1,103.68%[5] - Basic and diluted earnings per share were both ¥0.5153, an increase of 624.75% year-on-year[6] - The total operating revenue for Q1 2023 was CNY 193,032,111.71, a significant increase from CNY 67,225,376.61 in Q1 2022, representing a growth of approximately 187.5%[23] - The net profit for Q1 2023 reached CNY 74,198,500.21, a substantial rise from CNY 7,312,622.81 in Q1 2022, reflecting an increase of approximately 907.5%[25] - The total comprehensive income attributable to the parent company for Q1 2023 was ¥74,586,123.06, compared to ¥7,714,539.65 in Q1 2022, representing a significant increase[26] - Basic and diluted earnings per share for Q1 2023 were both ¥0.5153, up from ¥0.0711 in Q1 2022, indicating a substantial improvement in profitability[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,030,520,823.98, an increase of 5.56% from the end of the previous year[6] - As of March 31, 2023, the company's total current assets amounted to RMB 1,862,705,981.47, an increase from RMB 1,756,545,255.66 as of December 31, 2022, representing a growth of approximately 6.05%[18] - The company's total assets as of Q1 2023 amounted to CNY 2,030,520,823.98, up from CNY 1,923,657,055.17 in the previous year, marking an increase of about 5.6%[20] - The total liabilities for Q1 2023 were CNY 440,880,924.65, compared to CNY 408,641,670.42 in Q1 2022, which is an increase of approximately 7.9%[20] Cash Flow - The net cash flow from operating activities was ¥49,621,308.92, reflecting a significant increase in cash received from sales compared to the same period last year[10] - Net cash flow from operating activities for Q1 2023 was ¥49,621,308.92, a turnaround from a negative cash flow of ¥6,188,908.59 in Q1 2022[28] - Cash inflow from operating activities totaled ¥252,235,785.99 in Q1 2023, compared to ¥75,744,422.97 in the same period last year, reflecting a growth of 233%[28] - Cash outflow for operating activities was ¥202,614,477.07 in Q1 2023, compared to ¥81,933,331.56 in Q1 2022, showing an increase of 147%[28] - The company reported a net increase in cash and cash equivalents of ¥20,292,229.89 for Q1 2023, contrasting with a decrease of ¥16,713,855.22 in Q1 2022[28] - The ending balance of cash and cash equivalents as of the end of Q1 2023 was ¥1,488,164,956.19, compared to ¥154,809,279.39 at the end of Q1 2022[28] Research and Development - Research and development expenses totaled ¥6,061,357.91, accounting for 3.14% of operating revenue, down from 5.55%[6] - The company's R&D expenses in Q1 2023 were CNY 5,933,038.80, up from CNY 3,983,811.33 in Q1 2022, indicating a growth of about 48.9%[23] Shareholder Information - The company reported a total of 7,334 common shareholders at the end of the reporting period[12] - The company has identified several key shareholders, with the largest holding being China Industrial Bank Co., Ltd. with 1,384,146 shares[14] Subsidiary Transfers - The company decided to transfer its subsidiary, Chongqing Shanchuan Blood Dialysis Center Co., Ltd., for RMB 4 million due to high operational costs[15] - Another subsidiary, Junlian Kanda Blood Dialysis Center Co., Ltd., was also transferred for RMB 2.5 million, again due to ongoing losses[15] Inventory and Receivables - The company's inventory increased to RMB 180,093,298.00 from RMB 133,686,275.33, marking a rise of about 34.8%[18] - The company reported an increase in accounts receivable to RMB 117,121,708.93 from RMB 116,035,138.39, a slight increase of about 0.93%[18] - The prepayments rose to RMB 22,786,725.80 from RMB 9,787,626.87, showing an increase of approximately 132.5%[18] Financial Activities - The company has not reported any significant changes in its financing and securities business activities during the reporting period[14] - The company is not applying new accounting standards or interpretations for the first time in 2023, ensuring consistency in financial reporting[29]